CN107405405B - 治疗和/或预防慢性阻塞性肺病的新组合物和方法 - Google Patents

治疗和/或预防慢性阻塞性肺病的新组合物和方法 Download PDF

Info

Publication number
CN107405405B
CN107405405B CN201680008472.9A CN201680008472A CN107405405B CN 107405405 B CN107405405 B CN 107405405B CN 201680008472 A CN201680008472 A CN 201680008472A CN 107405405 B CN107405405 B CN 107405405B
Authority
CN
China
Prior art keywords
cxcr4
ccr2
copd
ccr3
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680008472.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN107405405A (zh
Inventor
帕特里克·伯杰
伊莎贝尔·杜宾
皮尔-奥利弗·吉罗代
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Santé et de la Recherche Médicale
Centre Hospitalier Universitaire de Bordeaux
Université de Bordeaux
Original Assignee
Institut National de la Santé et de la Recherche Médicale
Centre Hospitalier Universitaire de Bordeaux
Université de Bordeaux
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Santé et de la Recherche Médicale, Centre Hospitalier Universitaire de Bordeaux, Université de Bordeaux filed Critical Institut National de la Santé et de la Recherche Médicale
Publication of CN107405405A publication Critical patent/CN107405405A/zh
Application granted granted Critical
Publication of CN107405405B publication Critical patent/CN107405405B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7158—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CN201680008472.9A 2015-01-28 2016-01-28 治疗和/或预防慢性阻塞性肺病的新组合物和方法 Active CN107405405B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15152886.6A EP3050574B1 (en) 2015-01-28 2015-01-28 Use of plerixafor for treating and/or preventing acute exacerbations of chronic obstructive pulmonary disease
EPEP151528866 2015-01-28
PCT/EP2016/051771 WO2016120369A1 (en) 2015-01-28 2016-01-28 New compositions and methods of treating and/or preventing chronic obstructive pulmonary disease

Publications (2)

Publication Number Publication Date
CN107405405A CN107405405A (zh) 2017-11-28
CN107405405B true CN107405405B (zh) 2021-05-11

Family

ID=52434596

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680008472.9A Active CN107405405B (zh) 2015-01-28 2016-01-28 治疗和/或预防慢性阻塞性肺病的新组合物和方法

Country Status (12)

Country Link
US (1) US10813911B2 (enExample)
EP (2) EP3050574B1 (enExample)
JP (1) JP7127988B2 (enExample)
CN (1) CN107405405B (enExample)
AU (1) AU2016212067B2 (enExample)
BR (1) BR112017016347A2 (enExample)
CA (1) CA2972319C (enExample)
DK (1) DK3050574T3 (enExample)
EA (1) EA201791689A1 (enExample)
ES (1) ES2764840T3 (enExample)
IL (1) IL253688B2 (enExample)
WO (1) WO2016120369A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017127810A1 (en) * 2016-01-22 2017-07-27 Indiana University Research & Technology Corporation Methods for repairing lung tissue
TWI734027B (zh) * 2017-09-18 2021-07-21 泰宗生物科技股份有限公司 用於治療癌症之組合物
EP4085910A1 (en) * 2021-05-05 2022-11-09 4Living Biotech Use of a compound such as plerixafor for treating a viral pulmonary disease
CN119925562B (zh) * 2023-11-03 2025-11-28 中国科学院上海药物研究所 趋化因子受体2拮抗剂在制备治疗糖尿病并发焦虑症的应用
KR20250133491A (ko) * 2024-02-28 2025-09-08 재단법인 오송첨단의료산업진흥재단 인간 ccl7에 결합하는 신규한 항체 및 이의 용도
CN118252937B (zh) * 2024-04-07 2024-10-22 中山大学 Cxcr4受体的拮抗剂在抗埃博拉病毒感染中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009074807A2 (en) * 2007-12-12 2009-06-18 Imperial Innovations Limited Methods
WO2013052844A1 (en) * 2011-10-07 2013-04-11 Pulmatrix, Inc. Methods for treating and diagnosing respiratory tract infections
WO2014132100A1 (en) * 2013-03-01 2014-09-04 Mater Medical Research Institute Limited Mobilizing agents and uses therefor
WO2014143807A2 (en) * 2013-03-15 2014-09-18 Stromatt Scott Anti-cd37 antibody and bcr pathway antagonist combination therapy for treatment of b-cell malignancies and disorders

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5840867A (en) 1991-02-21 1998-11-24 Gilead Sciences, Inc. Aptamer analogs specific for biomolecules
GB9126677D0 (en) 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
ATE344324T1 (de) 1993-09-14 2006-11-15 Imp Innovations Ltd Eotaxin = eosinophil chemotaktisches cytokin
JP3367581B2 (ja) 1993-10-14 2003-01-14 小野薬品工業株式会社 新規なポリペプチド、その製造方法、そのポリペプチドをコードするｄｎａ、そのｄｎａからなるベクター、そのベクターで形質転換された宿主細胞
US6806061B1 (en) 1995-01-19 2004-10-19 Children's Medical Center Corporation G protein-coupled receptor gene and methods of use therefor
US6699843B2 (en) 1995-06-07 2004-03-02 Gilead Sciences, Inc. Method for treatment of tumors using nucleic acid ligands to PDGF
WO1997024325A1 (en) 1995-12-28 1997-07-10 Takeda Chemical Industries, Ltd. DIPHENYLMETHANE DERIVATIVES AS MIP-1α/RANTES RECEPTOR ANTAGONISTS
EP0914319B1 (en) 1996-05-20 2001-11-21 Teijin Limited Diarylalkyl cyclic diamine derivatives as chemokine receptor antagonists
AU6133098A (en) 1997-01-21 1998-08-07 Merck & Co., Inc. 3,3-disubstituted piperidines as modulators of chemokine receptor activity
SK112899A3 (en) 1997-02-26 2001-05-10 Pfizer Heteroaryl-hexanoic acid amide derivatives, their preparation and their use as selective inhibitors of mip-1-alpha binding to its ccr1 receptor
US6207155B1 (en) 1997-05-07 2001-03-27 Schering Corporation Method of eosinophil depletion with antibody to CCR 3 receptor
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
WO1999036518A1 (en) 1998-01-15 1999-07-22 Btg International Limited Ribozymal nucleic acids cleaving ccr5 or cxcr4
CA2321962C (en) 1998-02-27 2014-07-15 The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services G protein-coupled receptor antagonists
US6180348B1 (en) 1998-04-20 2001-01-30 Weihua Li Method of isolating target specific oligonucleotide ligands
CA2235420A1 (en) 1998-06-17 1999-12-17 Paolo Renzi Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation
US6429308B1 (en) 1998-11-24 2002-08-06 Hisamitsu Pharmaceutical Co., Inc. HIV infection inhibitors
US6723538B2 (en) 1999-03-11 2004-04-20 Micromet Ag Bispecific antibody and chemokine receptor constructs
IL145401A0 (en) 1999-03-24 2002-06-30 Anormed Inc Chemokine receptor binding heterocyclic compounds
AU2001233277B2 (en) 2000-02-03 2004-06-03 Millennium Pharmaceuticals, Inc. Humanized anti-ccr2 antibodies and methods of use therefor
GB2361704C (en) 2000-03-03 2006-08-02 Cambridge Antibody Tech Human antibodies against eotaxin and their use
US6946546B2 (en) 2000-03-06 2005-09-20 Cambridge Antibody Technology Limited Human antibodies against eotaxin
GB0016138D0 (en) 2000-06-30 2000-08-23 Novartis Ag Organic compounds
US20020147312A1 (en) 2001-02-02 2002-10-10 O'keefe Theresa Hybrid antibodies and uses thereof
US20050124569A1 (en) 2001-05-18 2005-06-09 Sirna Therapeutics, Inc. RNA interference mediated inhibition of CXCR4 gene expression using short interfering nucleic acid (siNA)
EP2990394A1 (en) 2001-11-30 2016-03-02 Biogen MA Inc. Antibodies against monocyte chemotactic proteins
AR041786A1 (es) 2002-03-15 2005-06-01 Novartis Ag Derivados de azetidina como antagonistas del receptor ccr-3, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la elaboracion de un medicamento
GB0212357D0 (en) 2002-05-29 2002-07-10 Glaxo Group Ltd Novel compounds
JP2006502107A (ja) 2002-07-02 2006-01-19 エフ．ホフマン−ラ　ロシュ　アーゲー Ｃｃｒ−３レセプターアンタゴニストｉｘとしての２，５−置換ピリミジン誘導体
US7964194B2 (en) 2002-11-15 2011-06-21 Morehouse School Of Medicine Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation
PL378753A1 (pl) 2003-02-27 2006-05-15 F.Hoffmann-La Roche Ag Antagoniści receptora CCR-3
US20050069955A1 (en) 2003-06-30 2005-03-31 Daniel Plaksin Antibodies and uses thereof
AR046594A1 (es) 2003-10-16 2005-12-14 Applied Research Systems Usos terapeuticos de variantes de quemoquina
AU2005214287A1 (en) 2004-02-20 2005-09-01 Genesis Research And Development Corporation Limited Targeted delivery of RNA interference molecules for the treatment of IgE-mediated disorders
ATE425161T1 (de) 2004-05-26 2009-03-15 Janssen Pharmaceutica Nv Mercaptoimidazole als ccr2-rezeptorantagonisten
KR20070063562A (ko) 2004-09-28 2007-06-19 얀센 파마슈티카 엔.브이. 치환 디피페리딘 ｃｃｒ２ 길항제
AU2006203826A1 (en) 2005-01-07 2006-07-13 Emory University CXCR4 antagonists for the treatment of HIV infection
US7622583B2 (en) 2005-01-14 2009-11-24 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
TW200716174A (en) 2005-05-19 2007-05-01 Centocor Inc Anti-MCP-1 antibodies, compositions, methods and uses
GB0517966D0 (en) 2005-09-02 2005-10-12 Novartis Ag Organic compounds
HUP0500877A2 (en) 2005-09-22 2007-05-29 Sanofi Aventis Amide derivatives as ccr3 receptor ligands, process for producing them, pharmaceutical compositions containing them and their use and intermediates
EP2041568A4 (en) 2006-06-15 2009-08-12 CCR2 ANTAGONISTS FOR CHRONIC BREATHING REACTIONS IN ORGAN TRANSPLANTATIONS
ATE537166T1 (de) 2006-10-27 2011-12-15 Boehringer Ingelheim Int Piperidylpropanthiole als ccr3-modulatoren
HRP20110551T1 (hr) 2007-05-30 2011-09-30 Eli Lilly & Company Antagonisti cikličkog peptida cxcr4
CA2692761C (en) 2007-07-12 2013-04-30 Chemocentryx, Inc. Fused heteroaryl pyridyl and phenyl benzenesulfonamides as ccr2 modulators for the treament of inflammation
HUP0800478A2 (en) 2008-07-31 2010-03-01 Sanofi Aventis Substituted pyrrolidinyl-[1,3]thiazolo[4,5-b]pyridin derivatives as ccr3 receptor ligands
WO2010069979A1 (en) 2008-12-16 2010-06-24 Nycomed Gmbh Pyran derivatives as ccr3 modulators
ES2551557T3 (es) 2008-12-19 2015-11-19 Boehringer Ingelheim International Gmbh Pirimidin-4-carboxamidas cíclicas como antagonistas del receptor CCR2 para el tratamiento de inflamaciones, asma y EPOC
US8278302B2 (en) 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
ES2528625T3 (es) 2009-04-17 2015-02-11 Janssen Pharmaceutica Nv Antagonistas de 4-azetidinil-1-fenil-ciclohexano de CCR2
US8471004B2 (en) 2009-10-07 2013-06-25 Hoffman-La Roche Inc. Bicyclic compounds
US8445674B2 (en) 2009-10-21 2013-05-21 Hoffmann-La Roche Inc Heterocyclyl compounds
JP5356323B2 (ja) * 2010-07-01 2013-12-04 富士化学工業株式会社 新規な非晶質ボセンタン及びその製造方法
US20120088769A1 (en) * 2010-10-11 2012-04-12 Axikin Pharmaceuticals, Inc. Salts of arylsulfonamide ccr3 antagonists
EP2646429B1 (en) 2010-12-01 2014-10-15 Janssen Pharmaceutica NV 4-substituted-cyclohexylamino-4-piperidinyl-acetamide antagonists of ccr2
US20140005174A1 (en) 2011-03-17 2014-01-02 Anilkumar G. Nair Indole derivatives useful as ccr2 antagonists
WO2012138880A2 (en) 2011-04-07 2012-10-11 The Brigham And Women's Hospital, Inc. Methods of treating inflammatory diseases by targeting the chemoattractant cytokine receptor 2 (ccr2) or chemokine (c-c motif) ligand 2 (ccl2)
AU2012258575B2 (en) * 2011-05-25 2017-03-02 Intermune, Inc. Pirfenidone and anti-fibrotic therapy in selected patients
DK2723360T3 (en) 2011-06-27 2017-08-28 Univ Pierre Et Marie Curie Paris 6 CCR2 antagonist peptides
WO2013057545A1 (en) * 2011-10-18 2013-04-25 Biocon Limited Acid addition salts of bosentan
US8822460B2 (en) 2012-04-06 2014-09-02 Janssen Pharmaceutica Nv Fused cyclopentyl antagonists of CCR2

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009074807A2 (en) * 2007-12-12 2009-06-18 Imperial Innovations Limited Methods
WO2013052844A1 (en) * 2011-10-07 2013-04-11 Pulmatrix, Inc. Methods for treating and diagnosing respiratory tract infections
WO2014132100A1 (en) * 2013-03-01 2014-09-04 Mater Medical Research Institute Limited Mobilizing agents and uses therefor
WO2014143807A2 (en) * 2013-03-15 2014-09-18 Stromatt Scott Anti-cd37 antibody and bcr pathway antagonist combination therapy for treatment of b-cell malignancies and disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Increased circulating fibrocytes and their capacity of proliferation and differentiation in clinically unstable patients with chronic obstructive pulmonary disease;Chun-Hua Wang et al.;《European respiratory journal》;20140725;第42卷;第602页 *
The role of fibrocytes in bronchial remodelling during acute exacerbation of COPD;Annaig Ozier et al.;《European respiratory journal》;20140725;第42卷;第249页 *

Also Published As

Publication number Publication date
EP3050574B1 (en) 2019-10-09
EA201791689A1 (ru) 2017-11-30
AU2016212067A1 (en) 2017-09-14
IL253688A (en) 2017-09-28
CN107405405A (zh) 2017-11-28
JP2018505187A (ja) 2018-02-22
US10813911B2 (en) 2020-10-27
JP7127988B2 (ja) 2022-08-30
WO2016120369A1 (en) 2016-08-04
DK3050574T3 (da) 2020-01-20
EP3050574A1 (en) 2016-08-03
BR112017016347A2 (pt) 2018-03-27
AU2016212067B2 (en) 2020-10-08
US20180271831A1 (en) 2018-09-27
CA2972319C (en) 2023-08-01
IL253688B1 (en) 2023-01-01
EP3613435A1 (en) 2020-02-26
ES2764840T3 (es) 2020-06-04
CA2972319A1 (en) 2016-08-04
IL253688B2 (en) 2023-05-01

Similar Documents

Publication Publication Date Title
Liu et al. The chemokine CCL1 triggers an AMFR-SPRY1 pathway that promotes differentiation of lung fibroblasts into myofibroblasts and drives pulmonary fibrosis
AU2016212067B2 (en) New compositions and methods of treating and/or preventing chronic obstructive pulmonary disease
JP6031510B2 (ja) 異常な線維芽細胞増殖及び細胞外マトリックスの沈着を特徴とする疾患、症状又はプロセスを予防又は治療する組成物及び方法
CN111741752A (zh) Gpcr异聚体抑制剂及其用途
US9198900B2 (en) Treatment of peritoneal injury using JAK inhibitors
US20090175849A1 (en) NOTCH inhibition in the treatment or prevention of atherosclerosis
JP2018501201A (ja) 異常な線維芽細胞増殖および細胞外マトリックス沈着を特徴とする疾患、状態、またはプロセスを予防または処置するための組成物および方法
JP2025519561A (ja) Ｇｐｃｒ阻害剤及びその使用
WO2012170929A2 (en) Monoclonal antibody and antigens for diagnosing and treating lung disease and injury
US20090105281A1 (en) Methods of treating inflammation
Liu et al. Tacrolimus alleviates pulmonary fibrosis progression through inhibiting the activation and interaction of ILC2 and monocytes
US20240115569A1 (en) Methods for blocking her2 signaling for treating pulmonary fibrosis
US20110319405A1 (en) Treatment and prevention of diffuse parenchymal lung disease by selective active-site mTOR inhibitors
US20160095897A1 (en) Par-4 antagonists for use in the treatment or prevention of influenza virus type a infections
US9511086B2 (en) Method for improving immune system function by administering agents that inhibit DNA-dependent protein kinase-directed apoptosis
US12583929B2 (en) Method of treating acute respiratory distress syndrome
US20090239884A1 (en) Methods of Treating Inflammation
EA040016B1 (ru) Применение композиции, содержащей антагонист или ингибитор рецептора хемокинов cxcr4 для изготовления лекарственного средства для предупреждения и/или лечения copd и aecopd, способ подавления миграции фиброцитов у пациентов с copd или aecopd и набор
JP6649376B2 (ja) 肺の炎症を治療する方法
Andrew et al. RPC4046, A Novel Anti-interleukin-13 Antibody, Blocks IL-13 Binding to IL-13 a1 and a2 Receptors: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation First-in-Human Study
WO2025226628A1 (en) Use of il-6 inhibitors for preventing or inhibiting lung transplantation rejection in a subject

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant